Form 8-K - Current report:
SEC Accession No. 0001493152-26-012062
Filing Date
2026-03-23
Accepted
2026-03-23 08:00:14
Documents
12
Period of Report
2026-03-23
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 41515
2 EX-3.1 ex3-1.htm EX-3.1 11096
  Complete submission text file 0001493152-26-012062.txt   221838

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ensc-20260323.xsd EX-101.SCH 3011
4 XBRL LABEL FILE ensc-20260323_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE ensc-20260323_pre.xml EX-101.PRE 22356
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3386
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

EIN.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 26779933
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)